These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1613270)

  • 21. CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene.
    Biassoni R; Ferrini S; Prigione I; Moretta A; Long EO
    J Immunol; 1988 Mar; 140(5):1685-9. PubMed ID: 2894394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triggering of the cytotoxic activity of murine natural killer and lymphokine-activated killer cells through the NK2.1 antigen.
    Morelli L; Lemieux S
    J Immunol; 1993 Dec; 151(12):6783-93. PubMed ID: 8258690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells.
    Midis GP; Gupta VK; Fabian DF; Lefor AT
    J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphokine-activated killer (LAK) cell purging of bone marrow.
    Cramer DV; Long GS
    Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphokine-activated killer cell activity of CD4-CD8- TCR alpha beta + thymocytes.
    Arase H; Arase-Fukushi N; Good RA; Onoé K
    J Immunol; 1993 Jul; 151(2):546-55. PubMed ID: 8335898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
    Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
    Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
    Falk CS; Noessner E; Weiss EH; Schendel DJ
    Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A scanning electron microscopy analysis of human cytotoxic cell subsets and of their mode of conjugation with tumor cell targets.
    Malorni W; Arancia G; Iosi F; Donelli G; Zarcone D; Moretta A; Grossi CE
    Scanning Microsc; 1989 Sep; 3(3):919-26; discussion 926-7. PubMed ID: 2617272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS; Hargrove ME; Ting CC
    J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of major histocompatibility complex class I antigens in modulating the performance of murine tumour cells in cold target competition assays.
    Haridas V; Saxena RK
    Immunology; 1995 Jan; 84(1):86-90. PubMed ID: 7890307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.